Self-pay patients with obesity now have additional Zepbound vial options, including 2.5 mg, 5 mg, 7.5 mg, and 10 mg doses. In addition to expanding the doses available, Lilly is taking steps to ...

(RTTNews) - Eli Lilly and Company (LLY) has launched 7.5 mg and 10 mg Zepbound single-dose vials for $499 under the Zepbound Self Pay Journey Program, making the obesity medication more affordable ...

Self-pay patients with obesity now have additional Zepbound vial options, including 2.5 mg, 5 mg, 7.5 mg and 10 mg doses. In addition to expanding the doses available, Lilly is taking steps to ...

Starting July 1, CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor Novo Nordisk, will still be covered under plans managed by ...

Patients with obesity who choose to self pay will soon be able to access the complete range of Zepbound single-dose vials, including 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg. Patients on ...

Pharmaceutical giants introduce an insurance-free pathway for top anticoagulant Eliquis, following similar direct-to-patient models from Eli Lilly and Novo Nordisk.

1 Zepbound Self Pay Journey Program lowers the price of the 7.5 mg, 10 mg, 12.5 mg and 15 mg vials only on first fill and when prescriptions are refilled within 45 days of their previous delivery.

Self-pay patients with obesity now have additional Zepbound vial options, including 2.5 mg, 5 mg, 7.5 mg and 10 mg doses. In addition to expanding the doses available, Lilly is taking steps to ...

Self-pay patients with obesity now have additional Zepbound vial options, including 2.5 mg, 5 mg, 7.5 mg and 10 mg doses. In addition to expanding the doses available, Lilly is taking steps to ...